Preliminary activity and favorable safety were observed among patients with heavily pretreated, triple-class refractory, relapsed/refractory multiple myeloma who received single-agent gintemetostat (KTX-1001), according to a presentation on…
Gintemetostat Has Single-Agent Activity in Pretreated R/R Multiple Myeloma
